Skeletal muscle depletion is associated with disease progression during neo-adjuvant therapy for borderline resectable pancreatic adenocarcinoma

被引：0
|
作者：
Griffin, O. M.
Ryan, R.
Duggan, S. N.
Geoghegan, J.
Conlon, K. C.
机构：
[1] Trinity Coll Dublin, Dept Surg, Trinity Ctr Hlth Sci, Natl Surg Ctr Pancreat Canc, Dublin, Ireland
[2] St Vincents Univ Hosp, Dept Radiol, Dublin, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2017年 / 186卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
13
引用
收藏
页码：S76 / S77
页数：2
相关论文
共 31 条
  • [21] Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma
    Glazer, Evan S.
    Rashid, Omar M.
    Pimiento, Jose M.
    Hodul, Pamela J.
    Malafa, Mokenge P.
    SURGERY, 2016, 160 (05) : 1288 - 1293
  • [22] Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
    Schwarz, Lilian
    Vernerey, Dewi
    Bachet, Jean-Baptiste
    Tuech, Jean-Jacques
    Portales, Fabienne
    Michel, Pierre
    Cunha, Antonio Sa
    BMC CANCER, 2018, 18
  • [23] Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: A multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
    Schwarz, Lilian
    Bachet, Jean-Baptiste
    Meurisse, Aurelia
    Bouche, Olivier
    Assenat, Eric
    Piessen, Guillaume
    Terrebonne, Eric
    Hammel, Pascal
    Regenet, Nicolas
    Turco, Celia
    Taieb, Julien
    Mabrut, Jean Yves
    Turrini, Olivier
    Portales, Fabienne
    Paye, Francois
    Barbier, Louise
    Truant, Stephanie
    Cunha, Antonio Sa
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
    Lilian Schwarz
    Dewi Vernerey
    Jean-Baptiste Bachet
    Jean-Jacques Tuech
    Fabienne Portales
    Pierre Michel
    Antonio Sa Cunha
    BMC Cancer, 18
  • [25] Correction to: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
    Lilian Schwarz
    Dewi Vernerey
    Jean-Baptiste Bachet
    Jean-Jacques Tuech
    Fabienne Portales
    Pierre Michel
    Antonio Sa Cunha
    BMC Cancer, 20
  • [26] Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVEC trial.
    Rohaan, Maartje W.
    Zijlker, Lisanne P.
    Stahlie, Emma H. A.
    Franke, Viola
    Wilgenhof, Sofie
    Van der Noort, Vincent
    Van Akkooi, Alexander Christopher Jonathan
    Haanen, John B. A. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Increase of serum androgen and its metabolites in postmenopausal primary breast cancer patients with disease progression during neo-adjuvant exemestane treatment; JFMC 34-0601 TR
    Takada, M.
    Saji, S.
    Honma, N.
    Masuda, N.
    Yamamoto, Y.
    Kuroi, K.
    Yamashita, H.
    Ohno, S.
    Aogi, K.
    Ueno, T.
    Toi, M.
    CANCER RESEARCH, 2012, 72
  • [28] Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study) (vol 18, 762, 2018)
    Schwarz, Lilian
    Vernerey, Dewi
    Bachet, Jean-Baptiste
    Tuech, Jean-Jacques
    Portales, Fabienne
    Michel, Pierre
    Cunha, Antonio Sa
    BMC CANCER, 2020, 20 (01)
  • [29] Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study
    Labori, Knut J.
    Katz, Matthew H.
    Tzeng, Ching W.
    Bjornbeth, Bjorn A.
    Cvancarova, Milada
    Edwin, Bjorn
    Kure, Elin H.
    Eide, Tor J.
    Dueland, Svein
    Buanes, Trond
    Gladhaug, Ivar P.
    ACTA ONCOLOGICA, 2016, 55 (03) : 265 - 277
  • [30] Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma is associated with equivalent morbidity and survival to pancreaticoduodenectomy without vein resection and should be the standard of care for patients with portal vein/SMV involvement and otherwise resectable disease
    Bartlett, David
    Marcon, Francesca
    Dasari, Bobby
    Marudanayagam, Ravi
    Sutcliffe, Robert
    Mirza, Darius
    Muiesan, Paulo
    Roberts, Keith
    BRITISH JOURNAL OF SURGERY, 2018, 105 : 45 - 45
1234